Noxopharm Ltd. · ASX:NOX
Peter Marks received 372,105 Noxopharm Ltd. shares as an award (Appendix 3Y, ASX)
Traded Nov 20, 2026 · Filed Nov 20, 2026
On Nov 20, 2026, Peter Marks (Director) received 372,105 Noxopharm Ltd. shares as an award at AUD 0.09 for AUD 33,750. Filed Nov 20, 2026 (Appendix 3Y, ASX).
- Awarded
- 372,105 shares
- Price
- AUD 0.09
- Value
- AUD 33,750
- Role
- Director
The filing in full
Appendix 3Y
*Rule 3.19A.2*
Change of Director’s Interest Notice
*Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.*
Introduced 30/09/01 Amended 01/01/11
| Name of entity | Noxopharm Limited |
|---|---|
| ABN | 50 608 966 123 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Peter Marks |
|---|---|
| Date of last notice | 1 March 2021 |
Part 1 - Change of director’s relevant interests in securities
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
| Direct or indirect interest | Indirect |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Shanti Capital Pty Ltd, an entity controlled by Peter Marks. |
| Date of change | 20 November 2026 |
| No. of securities held prior to change Shanti Capital Pty Ltd | 900,000 |
| Class | Ordinary |
| Number acquired | 372,105 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | These were issued for non-cash consideration, and issued at $0.0907 per Fully Paid Ordinary Share. |
| No. of securities held after change | 1,272,105 |
- See chapter 19 for defined terms.
---
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backShares issued in lieu of Directors’ fees following shareholder approval on 17 November 2026.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |
+ Part 3 – Closed period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
- See chapter 19 for defined terms.
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 20, 2026 | Ordinary | Award | 372,105 | AUD 0.09 |
Source
Download PDF · View original at ASX